



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com

产品名称: **(3 B,5 A,7 A)-3-[[3-((4-氨基丁基)氨基)丙基]氨基]胆甾烷-7,24-二醇  
 24-氢硫酸酯**  
 产品别名: 角鲨胺; **Squalamine; MSI-1256**

生物活性:																				
Description	<p>Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity. IC50 value: Target: in vitro: squalamine can strongly displace membrane-bound cationic proteins such as Rac1, a p-GTPase recruited to the inner leaflet of the eukaryotic cytoplasmic membrane for the actin remodeling necessary for endocytosis. At concentrations between 20 and 60 µg/mL, squalamine has been shown to inhibit a broad array of growth factor-induced, actin-dependent responses in endothelial cells, including cell migration, cell division, and vascular tube formation in a 3D matrix [1]. Squalamine effectively inhibited HBV replication in human primary hepatocytes when added either during the initial exposure of virus to the cells or at 24 h after infection. A similar study was performed to evaluate the effect of squalamine on the replication of HDV. Squalamine was introduced at 20 µg/mL during HDV exposure, and the effects were measured at day 7 when total RNA was extracted and assayed for HDV RNA sequences [1]. in vivo: one time daily treatment with squalamine (15 or 30 mg/kg per d s.c.) was started beginning on day 1 or 2 after viral administration and continuing until day 8 or 9, respectively. Survival was monitored, and animals that remained alive by day 21 were considered cured [1].</p>																			
	<p><b>In Vitro:</b>  <b>DMSO : 100 mg/mL (159.25 mM; Need ultrasonic)</b></p> <table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th>Solvent Mass Concentration</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>1.5925 mL</td> <td>7.9623 mL</td> <td>15.9246 mL</td> </tr> <tr> <td>5 mM</td> <td>0.3185 mL</td> <td>1.5925 mL</td> <td>3.1849 mL</td> </tr> <tr> <td>10 mM</td> <td>0.1592 mL</td> <td>0.7962 mL</td> <td>1.5925 mL</td> </tr> </tbody> </table>				Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	1 mM	1.5925 mL	7.9623 mL	15.9246 mL	5 mM	0.3185 mL	1.5925 mL	3.1849 mL	10 mM	0.1592 mL	0.7962 mL
Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg																
	1 mM	1.5925 mL	7.9623 mL	15.9246 mL																
5 mM	0.3185 mL	1.5925 mL	3.1849 mL																	
10 mM	0.1592 mL	0.7962 mL	1.5925 mL																	
Solvent&Solubility	<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。            储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p><b>In Vivo:</b>            请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：            ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.75 mg/mL (4.38 mM); Clear solution</p> <p>此方案可获得 ≥ 2.75 mg/mL (4.38 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 µL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 µL PEG300 中，混合均匀；向上述体系中加入 50 µL Tween-80，混合均匀；然后继续加入 450 µL 生理盐水定容至 1 mL。</p>																			
	<p>源叶生物</p>																			



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline)</p> <p>Solubility: ≥ 2.75 mg/mL (4.38 mM); Clear solution</p> <p>此方案可获得 ≥ 2.75 mg/mL (4.38 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 2.75 mg/mL (4.38 mM); Clear solution</p> <p>此方案可获得 ≥ 2.75 mg/mL (4.38 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
<b>References</b>	<p>[1]. Zasloff M, et al. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15978-83.</p> <p>[2]. Hraiech S, et al. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother. 2012 Oct;67(10):2452-8.</p> <p>[3]. Djouhri-Bouktab L, et al. Squalamine ointment for Staphylococcus aureus skin decolonization in a mouse model. J Antimicrob Chemother. 2011 Jun;66(6):1306-10.</p>

源叶生物